• Featured Product
  • KD/KO Validated

c-Met (N-terminal) Polyclonal antibody

c-Met (N-terminal) Polyclonal Antibody for FC, IHC, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, FC, ELISA

Conjugate

Unconjugated

Cat no : 19971-1-AP

Synonyms



Tested Applications

Positive WB detected inHeLa cells
Positive IHC detected inhuman breast cancer tissue, human colon tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive FC detected inHeLa cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:50-1:200
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 2 publications below

Product Information

19971-1-AP targets c-Met (N-terminal) in WB, IHC, FC, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide
Full Name met proto-oncogene (hepatocyte growth factor receptor)
Calculated molecular weight 156 kDa
Observed molecular weight 140 kDa, 50 kDa
GenBank accession numberNM_000245
Gene symbol MET
Gene ID (NCBI) 4233
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). This antibody recognizes the N-term of c-Met.

Publications

SpeciesApplicationTitle
humanWB

Carcinogenesis

MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1.

Authors - Wu Jianmin J
humanWB

Oncogene

A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.

Authors - F Yan